STOCK TITAN
  1. Home
  2. News
  3. FEMY

Femasys Inc. - FEMY STOCK NEWS

Welcome to our dedicated page for Femasys news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on Femasys stock.

Femasys Inc. (NASDAQ: FEMY) is a leading biomedical company dedicated to transforming women's healthcare through innovative solutions. The company focuses on developing and providing minimally invasive, non-surgical products that are accessible in-office, thus improving patient care and overall health economics. Femasys' mission addresses severely underserved areas in women's health, aiming to make a significant clinical impact worldwide.

The company's recent achievements include the FDA clearance and commercial launch of FemaSeed® Intratubal Insemination, a novel infertility treatment that enhances fertilization by delivering sperm directly to the fallopian tube. This product offers a cost-effective and less invasive alternative to traditional infertility treatments like IVF and ICSI. FemaSeed has demonstrated promising results, with a 24% pregnancy rate in severe male factor infertility cases.

Femasys is also advancing the development of FemBloc®, a non-surgical, in-office permanent birth control method currently in late-stage clinical trials. This product aims to provide a safer and more affordable option compared to long-standing surgical alternatives.

The company's diagnostic product portfolio includes FemVue® for fallopian tube assessment, FemCath® for selective fallopian tube evaluation, and FemCerv® for cervical cancer diagnosis. These products have achieved regulatory approvals in the U.S., Canada, and other international markets, and are ready for commercial deployment.

Femasys prides itself on its experienced management team, boasting over 200 years of collective industry expertise, and the guidance of world-class medical advisors. All products developed by Femasys adhere to stringent FDA regulations and ISO 13485 standards, ensuring the highest quality and compliance.

Recent news highlights include the first commercial procedure using FemaSeed, the release of promising topline data from pivotal trials, and significant capital infusion to support commercial initiatives into the second half of 2025. The company's strategic focus remains on the commercialization of its infertility and diagnostic product portfolios, ongoing pivotal trials, and addressing the critical unmet needs in women's healthcare.

News

Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives

Rhea-AI Summary
Femasys CEO and Founder Kathy Lee-Sepsick meets with Members of Congress to raise awareness of the company and discuss women's healthcare initiatives. The company focuses on addressing unmet needs of women with a portfolio of innovative products. President Biden's executive order for women's health initiatives has spurred interest in Femasys' solutions. The company offers minimally-invasive reproductive products and is developing a permanent birth control solution called FemBloc. Femasys recently announced positive topline data from its FemaSeed pivotal trial, showing a 24% pregnancy rate in women with male factor infertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
none
-
News

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update

Rhea-AI Summary
Femasys Inc. secures capital after FDA clearance of FemaSeed® to support commercial initiatives, with positive trial data and key appointments. Financially, R&D expenses increased, while sales decreased, resulting in a net loss, but the company expects to fund operations into 2H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.97%
Tags
earnings
-
News

Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape

Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) CEO Kathy Lee-Sepsick and CMO James Liu will discuss infertility treatment options, including FemaSeed®, in a virtual Fireside Chat with Jones Trading Analyst Catherine Novack. The event will focus on ART trends, FemaSeed's role, and challenges like rising IVF costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
News

Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility

Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announces positive topline data from its FemaSeed Localized Directional Insemination pivotal trial, showing a 24% pregnancy rate in women with severe male factor infertility. This rate is more than double the historic IUI rate, positioning FemaSeed as a cost-effective first-line treatment option. The majority of successful pregnancies occurred after the first FemaSeed procedure, with no new safety concerns reported. With FDA clearance and funding secured until 2025, Femasys is set to launch FemaSeed in the U.S. in the first half of this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
News

Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024

Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announces CEO Kathy Lee-Sepsick and CMO James Liu will join Jones Trading Analyst Catherine Novack in a discussion on infertility treatment options, including FemaSeed®. The event will focus on current trends in assisted reproductive technology and challenges like rising IVF costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
conferences
-
News

Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution

Rhea-AI Summary
Femasys Inc. announces the first commercial procedure using FemaSeed, an alternative to IVF, aiming to reshape female infertility management. Top-line pivotal data expected in Q1 2024 amidst ongoing uncertainty post-Alabama Supreme Court ruling.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.27%
Tags
none
News

Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF

Rhea-AI Summary
Femasys prepares to launch FemaSeed® in the U.S. amidst legal uncertainty after Alabama Supreme Court ruling. The company plans to release top-line data from a pivotal clinical trial in Q1 2024. FemaSeed offers a cost-effective and safe alternative to traditional assisted reproductive methods, aiming to revolutionize fertilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
clinical trial
-
News

Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer

Rhea-AI Summary
Femasys Inc. appoints Richard Spector as chief commercial officer to lead the commercial launch of FemaSeed, a novel solution for infertility, and FemBloc, a non-surgical permanent birth control. Mr. Spector brings 25 years of experience in leading public and private healthcare companies and will be granted 100,000 shares of Femasys common stock as an inducement for his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.25%
Tags
management
-
News

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women

Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) announced the activation of enrollment for its pivotal FemBloc trial at the University of California, Davis Medical Center. The trial aims to investigate the safety and efficacy of FemBloc, a non-surgical, permanent birth control candidate. This marks the third academic center to participate in the trial, with Dr. Mitchell Creinin as an initial advisor. The trial is designed to address the high unmet need for women seeking permanent birth control, for whom elective surgery remains the only option. Femasys is focused on creating accessible innovative options for women, with a broad portfolio of in-office, accessible solutions and late-stage clinical development for permanent birth control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
none
News

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology

Rhea-AI Summary
Femasys Inc. announces the activation of enrollment for its pivotal FemBloc trial at the University of Utah Hospital, led by Dr. Lori Gawron, M.D. The trial is designed to investigate the safety and efficacy of FemBloc, a non-surgical permanent birth control solution. The company is focused on providing accessible solutions for women worldwide, with a broad portfolio of products in late-clinical stage development and FDA-cleared products. The involvement of University of Utah Hospital and Dr. Gawron demonstrates support for FemBloc and its potential to provide improved birth control options for women.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none

FAQ

What is the current stock price of Femasys (FEMY)?

The current stock price of Femasys (FEMY) is $1.175 as of November 4, 2024.

What is the market cap of Femasys (FEMY)?

The market cap of Femasys (FEMY) is approximately 26.3M.

What is Femasys Inc. known for?

Femasys Inc. is known for developing innovative, in-office, minimally invasive solutions to address significant unmet needs in women's healthcare, including infertility treatments and diagnostic products.

What is FemaSeed?

FemaSeed is an FDA-cleared intratubal insemination product designed to enhance natural fertilization by delivering sperm directly to the fallopian tube, offering a less invasive and more affordable alternative to traditional infertility treatments like IVF.

What are the recent achievements of Femasys?

Recent achievements include the first commercial procedure using FemaSeed, FDA clearance for multiple products, promising trial data, and securing capital to support operations into the second half of 2025.

What is FemBloc?

FemBloc is a non-surgical, in-office permanent birth control method currently in late-stage clinical development, intended to provide a safer and more affordable alternative to traditional surgical options.

What diagnostic products does Femasys offer?

Femasys offers FemVue for fallopian tube assessment by ultrasound, FemCath for selective fallopian tube evaluation, and FemCerv for cervical cancer diagnosis.

How does Femasys ensure product quality?

Femasys ensures product quality by adhering to FDA regulations and ISO 13485 standards for all its manufacturing activities and products.

What markets has Femasys achieved regulatory approvals in?

Femasys has achieved regulatory approvals in the United States, Canada, and several other international markets.

Who leads Femasys Inc.?

Femasys is led by a management team with over 200 years of collective industry experience and the guidance of world-class medical advisors.

What are the financial prospects for Femasys?

Femasys has secured sufficient capital to fund operations into the second half of 2025, supporting its strategic focus on commercialization and advancing clinical trials.

Where can I learn more about Femasys' products and updates?

For more information about Femasys' products and latest updates, visit their website at www.femasys.com, or follow them on X, Facebook, and LinkedIn.

Stock FEMY logo
Femasys Inc.

Nasdaq:FEMY

FEMY Rankings

#5164 Ranked by Market Cap
N/A Ranked by Dividends

FEMY Stock Data

26.35M
22.23M
7.62%
7.1%
2.23%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
SUWANEE